Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Chiasma Inc (CHMA)

Chiasma Inc (CHMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer

SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive...

CHMA : 3.76 (-6.00%)
NRSN : 1.2699 (+1.59%)
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates RAVN, BOCH, ONEM, CHMA; Shareholders are Encouraged to Contact the Firm

NEW YORK, July 24, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

RAVN : 58.08 (+0.19%)
BOCH : 15.17 (-1.56%)
ONEM : 16.47 (+2.87%)
CHMA : 3.76 (-6.00%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates HGV, CHMA, ONDS, BOCH; Shareholders are Encouraged to Contact the Firm

NEW YORK, July 03, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

HGV : 37.44 (+1.52%)
CHMA : 3.76 (-6.00%)
ONDS : 0.7376 (-3.71%)
BOCH : 15.17 (-1.56%)
Chiasma Announces Submission of Marketing Authorization Application for MYCAPSSA® to the European Medicines Agency

Submission supported by previously announced data from Phase 3 MPOWEREDâ„¢ study

CHMA : 3.76 (-6.00%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds ARPO, ONDS, CHMA, and PFOH Shareholders About Its Ongoing Investigations

NEW YORK, June 24, 2021 (GLOBE NEWSWIRE) --

ARPO : 33.00 (-0.90%)
ONDS : 0.7376 (-3.71%)
CHMA : 3.76 (-6.00%)
PFOH : 40.2000 (+0.50%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds ONDS, CHMA, PFOH, and HGV Shareholders About Its Ongoing Investigations

NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) --

ONDS : 0.7376 (-3.71%)
CHMA : 3.76 (-6.00%)
PFOH : 40.2000 (+0.50%)
HGV : 37.44 (+1.52%)
Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.

Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.

LSE.LN : 8,620.000 (-0.58%)
AMYT : 14.70 (+0.07%)
CHMA : 3.76 (-6.00%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates PFPT, MDP, CHMA, EQT; Shareholders are Encouraged to Contact the Firm

NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

PFPT : 175.90 (-0.02%)
MDP : 59.07 (+0.12%)
CHMA : 3.76 (-6.00%)
EQT : 35.62 (-2.52%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds CHMA, PFOH, PTON, and HGV Shareholders About Its Ongoing Investigations

NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) --

CHMA : 3.76 (-6.00%)
PFOH : 40.2000 (+0.50%)
PTON : 7.25 (-14.71%)
HGV : 37.44 (+1.52%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds CHMA, PFOH, PTON, and HGV Shareholders About Its Ongoing Investigations

NEW YORK, June 03, 2021 (GLOBE NEWSWIRE) --

CHMA : 3.76 (-6.00%)
PFOH : 40.2000 (+0.50%)
PTON : 7.25 (-14.71%)
HGV : 37.44 (+1.52%)

Barchart Exclusives

Thanks to Wall Street, Novo Nordisk Stock is Now a Buy
Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a valuation a third cheaper than competitor, Eli Lilly. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar